Last updated on March 2019

A Phase 3 Study (PHOCUS) to determine whether the oncolytic virus immunotherapy called Pexa-Vec (JX-594) can slow the progression of advanced liver cancer (hepatocellular carcinoma or HCC).


Other Details:

Participants in both arms of the study will receive sorafenib at no charge.

For more information, please use the email response form or email the study at: Patient_Inquiry@sillajen.com or call (415) 530-4994

To find out more about the study, if you are qualified and how to participate, please visit our PHOCUS trial website by clicking here www.pexavectrials.com/en



Find a site near you

Start Over
Sorry. There are no research sites conducting this study in the radius provided. ( View all Sites )

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.